ARPINO, GRAZIA
ARPINO, GRAZIA
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M.
Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance.
2004 Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
2004 Arpino, Grazia; Stephanie J., Green; D., Craig Allred; Dannika, Lew; Silvana, Martino; C., Kent Osborne; Richard M., Elledge
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes
2005 Arpino, Grazia; H., Weiss; R., Elledge
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, Rm
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
2007 Arpino, Grazia; Carolina, Gutierrez; Heidi, Weiss; Mothaffar, Rimawi; Suleiman, Massarweh; Lavina, Bharwani; DE PLACIDO, Sabino; C., Kent Osborne; Rachel, Schiff
Triple-negative breast cancers: Biomarkers and outcomes
2010 Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia
Capitolo 4 - Terapia Medica
2011 G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco
Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer
2002 Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge
The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy.
2003 Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne
Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer
2003 Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin
Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome.
2002 Arpino, Grazia; Gary M., Clark; Syed, Mohsin; Valerie J., Bardou; Richard M., Elledge
Imaging tests in staging and surveillance of early breast cancer in Italy. changes in routine clinical practice and costs implications
2010 Cammarota, Simona; Menditto, Enrica; Citarella, Anna; Putignano, D.; Riegler, S.; Arpino, Grazia
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
2005 C., Kent Osborne; Rachel, Schiff; Arpino, Grazia; Adrian Susan, Lee; V. G., Hilsenbeck
Lobular neoplasia on core-needle biopsy--clinical significance.
2004 Arpino, Grazia; D., Craig Allred; Syed Khalid, Mohsin; Heidi L., Weiss; David, Conrow; Richard M., Elledge
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study
2002 Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts.
2006 M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition.
2004 Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R.
Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy.
2002 V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark
Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study.
2012 Arpino, Grazia; Pensabene, Matilde; Forestieri, Valeria; Condello, Caterina; Maria Anna Sarno, ; Ruocco, Raffaella; Cerillo, Ivana; DE ANGELIS, Carmine; Lauria, Rossella; Crispo, Anna; DE PLACIDO, Sabino
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M. | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm | |
| HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. | 1.1 Articolo in rivista | 2004 | Arpino, Grazia; Stephanie J., Green; D., Craig Allred; Dannika, Lew; Silvana, Martino; C., Kent Osborne; Richard M., Elledge | |
| Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes | 4.1 Articoli in Atti di convegno | 2005 | Arpino, Grazia; H., Weiss; R., Elledge | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, Rm | |
| Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. | 1.1 Articolo in rivista | 2007 | Arpino, Grazia; Carolina, Gutierrez; Heidi, Weiss; Mothaffar, Rimawi; Suleiman, Massarweh; Lavina, Bharwani; DE PLACIDO, Sabino; C., Kent Osborne; Rachel, Schiff | |
| Triple-negative breast cancers: Biomarkers and outcomes | 4.1 Articoli in Atti di convegno | 2010 | Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia | |
| Capitolo 4 - Terapia Medica | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco | |
| Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge | |
| The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy. | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne | |
| Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin | |
| Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. | 1.1 Articolo in rivista | 2002 | Arpino, Grazia; Gary M., Clark; Syed, Mohsin; Valerie J., Bardou; Richard M., Elledge | |
| Imaging tests in staging and surveillance of early breast cancer in Italy. changes in routine clinical practice and costs implications | 1.5 Abstract in rivista | 2010 | Cammarota, Simona; Menditto, Enrica; Citarella, Anna; Putignano, D.; Riegler, S.; Arpino, Grazia | |
| Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. | 1.1 Articolo in rivista | 2005 | C., Kent Osborne; Rachel, Schiff; Arpino, Grazia; Adrian Susan, Lee; V. G., Hilsenbeck | |
| Lobular neoplasia on core-needle biopsy--clinical significance. | 1.1 Articolo in rivista | 2004 | Arpino, Grazia; D., Craig Allred; Syed Khalid, Mohsin; Heidi L., Weiss; David, Conrow; Richard M., Elledge | |
| HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge | |
| Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts. | 4.1 Articoli in Atti di convegno | 2006 | M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff | |
| Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R. | |
| Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy. | 4.1 Articoli in Atti di convegno | 2002 | V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark | |
| Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study. | 4.1 Articoli in Atti di convegno | 2012 | Arpino, Grazia; Pensabene, Matilde; Forestieri, Valeria; Condello, Caterina; Maria Anna Sarno, ; Ruocco, Raffaella; Cerillo, Ivana; DE ANGELIS, Carmine; Lauria, Rossella; Crispo, Anna; DE PLACIDO, Sabino |